Investor Relations :: Sigyn Therapeutics, Inc. (SIGY)

Latest News

Dec 1, 2021

Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis

View Press Release

Aug 30, 2021

Sigyn Therapeutics Featured on National Public Radio: “Addressing the Cytokine Storm”

Aug 10, 2021

Sigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory Disease Targets

View All News

Sigyn Therapeutics Closing Bell Presentation

View Presentation

Q3 2021

Quarter Ended Sep 30, 2021

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Company Overview

Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

View Management Team View Board of Directors

Investor Contact Information

Company

Sigyn Therapeutics, Inc.
2468 Historic Decatur Rd.
Suite 140
San Diego, CA 92106
T: 619.353.0800